Abstract P1-02-06: Prediction of Prosigna® breast cancer intrinsic subtype by immunohistochemical ER, PR and Ki67 expression
Ulrike Heber(Comprehensive Cancer Center Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Florian Fitzal, Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Leonhard Müllauer(Hochschule Campus Wien), Stefan Heber(Medical University of Vienna), Rupert Bartsch(Universitätszahnklinik Wien), Ruth Exner(Comprehensive Cancer Center Vienna), Sabine Danzinger(Medical University of Vienna), Kristina Tendl-Schulz(Medical University of Vienna), Christian F. Singer(Comprehensive Cancer Center Vienna)
Cited by 2
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k